Building a winning portfolio is no easy task. One simple way to avoid many of the pitfalls that plague individual investors, though, is to start off with a stock with a history of delivering solid returns for a decade or more.
With this theme in mind, we turned to three of our Motley Fool contributors to get their take on which top stocks are worth considering as the cornerstone for a newly minted portfolio. They suggested…
A rock-solid pharma play
George Budwell (Pfizer): Pharmaceutical behemoth Pfizer may not jump out as a “must-own” stock, but this company has a lot to offer investors. In fact, this mega-cap drugmaker is arguably one of the best stocks to use as a base to build your broader portfolio.
Pfizer, after all, sports an outstanding dividend program and stellar free cash flows, and its long-term outlook continues to improve thanks to a rapidly growing oncology franchise. The company has also shown a penchant for producing outstanding returns on capital, even in the face of numerous headwinds, such as the drug pricing controversy in the U.S. and a slew of patent expirations.
Over the past 10 years, for instance, Pfizer has literally lost billions in annual sales due to the loss of exclusivity for blockbuster products like Celebrex, Lipitor, and Viagra. Yet the drugmaker’s stock still produced a total return on capital in excess of 324% over this 10-year period (including dividends and assuming a dividend reinvestment plan).
Now, that return on capital might not have beat most of the major markets during this period, but it’s impressive nonetheless. Simply to keep pace with the broader markets, after all, Pfizer had to overcome a litany of internal and external threats to its top line, while most of its peers were enjoying record-setting earnings and revenue hauls.
Put simply, most companies probably would have seen their share prices and underlying fundamentals drop off a cliff in the face of similar headwinds. But Pfizer’s stock didn’t miss a beat — even as the company’s product portfolio and business model both came under intense pressure. So with better days close at hand, Pfizer’s stock appears set to continue its steady climb northward, making it an outstanding equity to own as a foundational piece for any portfolio.
A top play in the video game space
Keith Noonan (Activision Blizzard): Recommending a stock that’s lost roughly half of its value over the last year as one to build a portfolio around might be controversial — and it’s fair to say that Activision Blizzard is a controversial stock at the moment. In addition to the big share price volatility, a few of the company’s key franchises are losing steam, and some analysts see its growth opportunities being significantly diminished in light of stricter content regulations in China and the emergence of new, high-profile competition such as Fortnite.
It’s clear that Activision Blizzard is going through a transitional period, but the big sell-offs and uncertainty surrounding its near-term outlook actually present a worthwhile opportunity to build a long-term position in a company that has historically been adept at navigating the challenges of its industry and has a lot of great assets.
Activision Blizzard still has some of the most talented development studios in the industry, and big franchises like…
Continue reading at THE MOTLEY FOOL